Cidara Therapeutics Ownership
| CDTX Stock | USD 20.21 0.01 0.05% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 4.6 M | Current Value 6.5 M | Avarage Shares Outstanding 2.1 M | Quarterly Volatility 1.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Cidara |
Cidara Stock Ownership Analysis
About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cidara Therapeutics recorded a loss per share of 23.9. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 24th of April 2024. Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Cidara Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Cidara Therapeutics please contact Jeffrey Stein at 858 752 6170 or go to https://www.cidara.com.Besides selling stocks to institutional investors, Cidara Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cidara Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cidara Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cidara Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Cidara Therapeutics Insider Trades History
About 5.0% of Cidara Therapeutics are currently held by insiders. Unlike Cidara Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cidara Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cidara Therapeutics' insider trades
Cidara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cidara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cidara Therapeutics backward and forwards among themselves. Cidara Therapeutics' institutional investor refers to the entity that pools money to purchase Cidara Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 31.8 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 19.5 K | State Street Corp | 2024-06-30 | 13.6 K | U.s. Bancorp | 2024-06-30 | 13.1 K | Ubs Group Ag | 2024-06-30 | 1.5 K | Acadian Asset Management Llc | 2024-06-30 | 855 | Tower Research Capital Llc | 2024-06-30 | 746 | Manchester Capital Management Llc | 2024-09-30 | 470 | Pacifica Partners Inc | 2024-09-30 | 400 | Ra Capital Management, Llc | 2024-09-30 | 703.1 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 703.1 K |
Cidara Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cidara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cidara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cidara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cidara Therapeutics Outstanding Bonds
Cidara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cidara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cidara bonds can be classified according to their maturity, which is the date when Cidara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US171779AL52 Corp BondUS171779AL52 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Cidara Therapeutics Corporate Filings
F4 | 29th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.